ACRS
NASDAQ
$5.57
Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $10 (+79.53%)
Market Cap
$782M
Free Cash Flow Yield
-6.69%
Beta (5Y)
0.86
Price Chart
Valuation
Market Cap$782M
P/S89.47
P/B5.44
Profitability
Total Revenue (TTM)$8.37M
Gross Profit (TTM)-$56M
EBITDA-$80M
Operating Margin-1112%
EPS-$0.58
Financial Health
Free Cash Flow Yield-6.69%
Growth & Risk
EPS 5Y CAGR-15.62%
Revenue 5Y CAGR+4.08%
FCF 5Y CAGR+3.33%
Beta (5Y)0.86
Sharpe Ratio1.67